SAHHEARTCardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients
Data Collection
Collected from today forward - ProspectiveBrain Diseases+8
+ Cardiovascular Diseases
+ Central Nervous System Diseases
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: February 1, 2012
Actual date on which the first participant was enrolled.Laboratory markers daily: Routine laboratory test (blood gases, haemoglobin, thrombocytes, leukocytes, INR, bilirubin, creatinine, c-reactive protein, CK, CK-MB, Tnt, BNP, sodium, potassium, magnesium) are taken at 8 a.m. Study laboratory tests (sensitive ischemia markers, remodelling marker MMP-9 and CgA as surrogate marker for increased sympathetic activity) are taken four times during study period at the same time as cardiac ECHOes and Holtering. Gene sample is taken once on day one. Primary outcome measurement is to document the incidence of myocardial dysfunction and the predictive factors during the hospital stay and at three months. Secondary outcome is to assess the impact of cardiac problems on morbidity and mortality during first three months.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.198 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 3 locations
Turku University Hospital
Turku, FinlandInselspital Bern
Bern, Switzerland